Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
June 2013, Vol 4, No 5
June 2013, Vol 4, No 5
Strongly Suppressing Testosterone during Androgen-Deprivation Therapy Prolongs Survival
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
A secondary analysis of a large study on intermittent versus continuous androgen-deprivation therapy (ADT) has confirmed the importance of aiming for very low testosterone levels in men after they are diagnosed with prostate cancer, according to new data presented at the 2013 Canadian Urological Association annual meeting.
Read Article
Off-Label Drug Use in Oncology Accounts for 18% of Spending
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
An examination of the Surveillance, Epidemiology and End Results (SEER)-Medicare database from 1998 to 2008 revealed that a significant number of patients with cancer receive drugs that are neither indicated by the US Food and Drug Administration (FDA) for the specific condition nor endorsed by the National Comprehensive Cancer Network (NCCN) compendia—and 18% of the spending on cancer drugs is for off-label drug use.
Read Article
Value of Genetic Research for Drug Development: 2 Genes Identify Who Will Benefit from Breast Cancer Prophylaxis
Value Propositions
,
Value Peer-spectives
June 2013, Vol 4, No 5
>A new study supported by the National Institutes of Health Pharmacogenomics Research Network represents a step forward toward personalized medicine in breast cancer prevention among women who are at high risk for the disease.
Read Article
FDA Requests More Data for Tivozanib
FDA Approvals, News & Updates
June 2013, Vol 4, No 5
The FDA denied the approval of a New Drug Application for tivozanib, which was submitted by its manufacturer (Aveo Pharmaceuticals/Astellas), for the treatment of renal-cell carcinoma.
Read Article
Lenalidomide Receives New Indication for Mantle- Cell Lymphoma
FDA Approvals, News & Updates
June 2013, Vol 4, No 5
The FDA approved lenalidomide capsules (Revlimid; Celgene Corporation) for the treatment of patients with mantle-cell lymphoma whose disease has relapsed or progressed after 2 previous therapies, one of which included bortezomib (Velcade). Lenalidomide is already approved for multiple myeloma (as is bortezomib).
Read Article
SGX942 Receives Fast Track Designation for Oral Mucositis
FDA Approvals, News & Updates
June 2013, Vol 4, No 5
Read Article
Meridian Cancer Care’s Multidisciplinary Approach to Patient Care
By
Mark J. Krasna, MD
Cancer Center Profile
June 2013, Vol 4, No 5
From the beginning, decisions about cancer treatment can be overwhelming. To help patients get back to the life and the people they love, Meridian Cancer Care offers every medical advantage. Medical collaboration is critical in the treatment of cancer. At Meridian Health, surgeons, medical oncologists, radiation oncologists, and other specialists work together to provide the best treatment plan for patients with cancer.
Read Article
New Guideline Emphasizes Sequenced Therapy for Castration-Resistant Prostate Cancer
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
June 2013, Vol 4, No 5
Evidence-based drug sequencing should form the basis of treatment for castration-resistant prostate cancer (CRPC), according to a new guideline from the American Urological Association (AUA) released at the 2013 AUA annual meeting.
Read Article
Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer
By
Lisa A. Raedler, PhD, RPh
Drug Updates
June 2013, Vol 4, No 5
Read Article
Patient-Reported Outcomes More Common in EU Labeling than FDA Labeling of Drug Approved for Lung Cancer
By
Neil Canavan
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
A study comparing patient-reported outcomes (PROs) labeling claims in Europe and in the United States showed that the European Medicines Agency (EMA) is more proactive in considering patient-generated feedback in their drug labeling decisions—this despite the US Food and Drug Administration (FDA)’s 2009 guidance that emphasized the importance of gathering and disseminating such data.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma